This study evaluates the efficacy and safety of LY-CoV555, a neutralizing monoclonal antibody, in treating mild or moderate Covid-19 in outpatients. The BLAZE-1 trial randomly assigned 452 patients to receive either LY-CoV555 at one of three doses (700 mg, 2800 mg, or 7000 mg) or a placebo. The primary outcome was the change in viral load from baseline at day 11. The results showed that the mean decrease in log viral load for the entire population was -3.81, eliminating more than 99.97% of viral RNA. The 2800 mg dose of LY-CoV555 significantly reduced viral load compared to placebo, while the 700 mg and 7000 mg doses showed smaller or no significant differences. Patients receiving LY-CoV555 had slightly less severe symptoms and a lower rate of hospitalization or emergency department visits compared to the placebo group. The safety profile of LY-CoV555 was similar to that of placebo, with no serious adverse events reported. The study suggests that LY-CoV555 may be effective in reducing viral load and improving symptoms in patients with mild or moderate Covid-19.This study evaluates the efficacy and safety of LY-CoV555, a neutralizing monoclonal antibody, in treating mild or moderate Covid-19 in outpatients. The BLAZE-1 trial randomly assigned 452 patients to receive either LY-CoV555 at one of three doses (700 mg, 2800 mg, or 7000 mg) or a placebo. The primary outcome was the change in viral load from baseline at day 11. The results showed that the mean decrease in log viral load for the entire population was -3.81, eliminating more than 99.97% of viral RNA. The 2800 mg dose of LY-CoV555 significantly reduced viral load compared to placebo, while the 700 mg and 7000 mg doses showed smaller or no significant differences. Patients receiving LY-CoV555 had slightly less severe symptoms and a lower rate of hospitalization or emergency department visits compared to the placebo group. The safety profile of LY-CoV555 was similar to that of placebo, with no serious adverse events reported. The study suggests that LY-CoV555 may be effective in reducing viral load and improving symptoms in patients with mild or moderate Covid-19.